Abstract: A YTHDF2 inhibitor, such as an antibody, a small molecule, an aptamer, a nucleic acid, a protein, or an enzyme, can be used for inhibiting expression of YTHDF2 in tumor-associated macrophages (TAMs) and in methods of treating cancer. T helper 9 cells that do not express a YTHDF2 protein are useful in inducing an immune response and treating cancer.

Abstract: Provided herein, inter alia, are PD-L1(+) natural killer cells that express soluble IL-15, PD-L1(+) natural killer cells that express soluble IL-15 and truncated EGFR, and methods of treating cancer using the PD-L1(+) natural killer cells. In an aspect is provided a method of treating cancer in a patient in need thereof comprising administering to the patient an effective amount of PD-L1(+) natural killer cells that express soluble IL-15.

Abstract: Provided herein, inter alia, are oncolytic viruses that express recombinant proteins having bispecific activity. The recombinant proteins include a first fusion protein comprising a first Fc domain covalently linked to a chemokine domain, and a second Fc fusion protein comprising a second Fc domain covalently linked to an anticancer therapeutic antibody domain. The recombinant proteins and oncolytic viruses provided herein are contemplated to be effective for the treatment of cancer, particularly by trafficking immune cells to the tumor microenvironment.

Abstract: Provided herein, inter alia, are methods for expanding a population of human group 2 innate lymphoid cells (ILC2), and methods of treating cancer in a subject including administering to the subject the population of expanded human ILC2. Further provided are genetically engineered human ILC2s including chimeric antigen receptors, and methods of treating cancer in a subject including administering to the subject the genetically engineered human ILC2.

Abstract: Provided herein, inter alia, are genetically-modified natural killer (NK) cells capable of expressing platelet-derived growth factor (PDGF) and/or platelet-derived growth factor receptor (PDGFR); pharmaceutical compositions comprising the genetically-modified natural killer (NK) cells; methods of treating cancer with the genetically-modified natural killer (NK) cells; and methods of expanding a population of NK cells using PDGF.

Abstract: Described herein are compositions comprising human natural killer (NK) cells engineered to reduce or eliminate Cbl-b and with or without a chimeric antigen receptor (CAR), methods of making such compositions, and methods of using such compositions (e.g., killing cancer cells, treating a subject having cancer or viral infection).

Abstract: This disclosure features novel cell lines and related methods for producing human natural killer (NK) cells, compositions of the NK cells produced by these methods, and uses thereof.

Abstract: Provided herein are, inter alia, compositions comprising ex vivo expanded ILC1 cells, methods of preparing the compositions, and methods useful for treating cancer and leukemia.

Abstract: Described herein, inter alia, are methods of treating a coronavirus infection.

Abstract: Nucleic acid molecules encoding an IL-15 domain and a chimeric antigen receptor (CAR) that targets cells expressing prostate stem cell antigen are provided as well as polypeptides encoded thereby. Vectors and host cells such as immune cells containing the nucleic acid molecules also are disclosed, as well as methods for their use.

Abstract: Chimeric antigen receptors (CAR) targeted to SARS-CoV-2 Spike protein and NK cells expressing such CAR are described. The CAR are targeted to SARS-CoV-2 Spike protein via an scFv or a variant human ACE2 protein. In some cases, the NK cells also express human IL-15 or a soluble fragment thereof.

Abstract: Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing CD47 antibody for the treatment of diseases including cancer, immune disorders, and infectious disease.

Abstract: Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing human IL-15 and human IL-15R?-sushi domain for the treatment of cancer and immune disorders. The recombinant oncolytic viruses may be used in combination with immune cells expressing chimeric antigen receptors (CAR) targeting EGFR and EGFR mutants.

Abstract: Provided herein are antibodies, recombinant proteins, and methods of use thereof including, for example, immunoglobulin G (IgG) antibodies and recombinant proteins including a Fab region and an Fc region connected through a hinge region, where the hinge region is resistant to cleavage by a protease. Also, provided herein, inter alia, are immunoglobulin G (IgG) antibodies and recombinant proteins including a Fab region and an Fc region connected through a hinge region, and where the Fc region has higher affinity for a ligand compared to a wildtype Fc.

Abstract: Provided herein are, inter alia, compositions including recombinant oncolytic herpes simplex viruses that express SARS-CoV spike (S) protein and viral vectors including nucleic acid sequences encoding SARS-CoV S protein. The compositions are useful for eliciting antibodies to SARS-CoV. The compositions are contemplated to be particularly useful for methods of treating and preventing SARS coronavirus infections in cancer patients.

Abstract: Provided herein are methods of treating cancer in a subject including detecting an amount of PD-L1(+) natural killer (NK) cells in a biological sample from the subject and treating the subject with an anti cancer therapy. Provided herein are methods of treating cancer in a patient including isolating natural killer (NK) cells from a subject, producing a population of PD-L1(+) NK cell from the isolated NK cells, and administering the population of PD-L1(+) NK cells into the patient.

Abstract: Disclosed are methods of mobilizing hematopoietic cells in a subject by administering to the subject a combination of Flt3 ligand (FLT3L) and a cell adhesion inhibitor. Also disclosed are methods of mobilizing hematopoietic cells in a cell culture population by contacting the cell culture population with Flt3 ligand. Mobilized hematopoietic cells can subsequently be harvested and used for hematopoietic cell transplantation. Further disclosed are compositions comprising a FLT3L, compositions comprising FLT3L and a cell adhesion inhibitor, and composition comprising FLT3L and Plerixafor.

Abstract: Methods and compositions involving miR-122, miR-15b, miR-21, and miR-155, which are useful for the treatment of various diseases, such as cancers, are described. Further described are methods and compositions useful for increasing, activating, or regulating NK cells and surface antigens.

Abstract: Methods and compositions involving miR-122, miR-15b, miR-21, and miR-155, which are useful for the treatment of various diseases, such as cancers, are described. Further described are methods and compositions useful for increasing, activating, or regulating NK cells and surface antigens.

Abstract: Disclosed are methods of mobilizing hematopoietic cells in a subject by administering to the subject a combination of Flt3 ligand (FLT3L) and a cell adhesion inhibitor. Also disclosed are methods of mobilizing hematopoietic cells in a cell culture population by contacting the cell culture population with Flt3 ligand. Mobilized hematopoietic cells can subsequently be harvested and used for hematopoietic cell transplantation. Further disclosed are compositions comprising a FLT3L, compositions comprising FLT3L and a cell adhesion inhibitor, and composition comprising FLT3L and Plerixafor.